New Molecular Scan Shows Promise for Mapping Clear Cell Kidney Cancer
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. It begins in the kidney’s filtering cells and gets its name from the appearance of the…
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. It begins in the kidney’s filtering cells and gets its name from the appearance of the…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…
A new Phase 2 clinical trial will begin this year to explore NKT2152 (a HIF2a-inhibitor) in combination with Fotivda/Tivozanib (a VEGFR tyrosine kinase inhibitor) as a treatment for relapsed/refractory clear…
X4 Pharmaceuticals Inc. has recently published data from 3 different posters which were presented at the American Society of Hematology (ASH) Annual Meeting in Georgia. You can read the full…
According to a story from Targeted Oncology, an experimental combination therapy tested on patients with advanced clear cell renal cell carcinoma (ccRCC) appeared to show potential for efficacy in a…